Gilead Sciences, Inc.

SWX:GILD Stock Report

Market Cap: CHF 144.7b

Gilead Sciences Valuation

Is GILD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of GILD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: GILD (CHF118.88) is trading below our estimate of future cash flow value (CHF267.33)

Significantly Below Future Cash Flow Value: GILD is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GILD?

Key metric: As GILD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GILD. This is calculated by dividing GILD's market cap by their current earnings.
What is GILD's PE Ratio?
PE Ratio22.1x
EarningsUS$8.51b
Market CapUS$188.35b

Price to Earnings Ratio vs Peers

How does GILD's PE Ratio compare to its peers?

The above table shows the PE ratio for GILD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.6x
NOVN Novartis
22.2x7.38%CHF 238.8b
ROG Roche Holding
22.2x11.00%CHF 287.6b
BSLN Basilea Pharmaceutica
9.6x-9.15%CHF 700.4m
LONN Lonza Group
40.3x17.32%CHF 36.6b
GILD Gilead Sciences
22.1x6.81%CHF 188.3b

Price-To-Earnings vs Peers: GILD is good value based on its Price-To-Earnings Ratio (22.1x) compared to the peer average (23.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does GILD's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
GILD 22.1xIndustry Avg. 15.3xNo. of Companies8PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GILD is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the European Biotechs industry average (15.3x).

Price to Earnings Ratio vs Fair Ratio

What is GILD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GILD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GILD's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GILD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 118.88
CHF 116.14
-2.31%
9.53%CHF 131.42CHF 90.69n/a26
Feb ’27n/a
CHF 107.80
0%
10.33%CHF 122.91CHF 79.62n/a26
Jan ’27n/a
CHF 104.53
0%
10.48%CHF 120.81CHF 82.91n/a26
Dec ’26n/a
CHF 105.14
0%
10.58%CHF 123.14CHF 84.51n/a25
Nov ’26n/a
CHF 104.21
0%
10.22%CHF 120.70CHF 84.49n/a25
Oct ’26n/a
CHF 100.23
0%
10.19%CHF 115.57CHF 78.11n/a25
Sep ’26n/a
CHF 100.37
0%
9.69%CHF 114.89CHF 78.74n/a25
Aug ’26n/a
CHF 95.13
0%
11.14%CHF 112.71CHF 73.26n/a26
Jul ’26n/a
CHF 92.64
0%
11.26%CHF 111.08CHF 73.79n/a26
Jun ’26n/a
CHF 94.64
0%
11.71%CHF 115.18CHF 75.69n/a26
May ’26n/a
CHF 94.72
0%
12.09%CHF 116.14CHF 76.32n/a26
Apr ’26n/a
CHF 98.51
0%
13.93%CHF 123.45CHF 72.31n/a25
Mar ’26n/a
CHF 97.64
0%
11.31%CHF 117.37CHF 74.03n/a27
Feb ’26n/a
CHF 91.54
0%
12.95%CHF 113.67CHF 66.38n/a27
Jan ’26n/a
CHF 88.84
0%
12.62%CHF 112.26CHF 65.56n/a27
Dec ’25n/a
CHF 85.65
0%
12.79%CHF 110.06CHF 60.75n/a28
Nov ’25n/a
CHF 76.16
0%
13.89%CHF 106.53CHF 59.76n/a28
Oct ’25n/a
CHF 71.20
0%
14.07%CHF 101.42CHF 58.38n/a27
Sep ’25n/a
CHF 70.28
0%
14.13%CHF 100.24CHF 57.70n/a27
Aug ’25n/a
CHF 73.52
0%
15.06%CHF 106.09CHF 59.73n/a27
Jul ’25n/a
CHF 74.21
0%
14.22%CHF 106.45CHF 59.93n/a26
Jun ’25n/a
CHF 74.61
0%
13.99%CHF 105.56CHF 60.45n/a26
May ’25n/a
CHF 76.93
0%
12.99%CHF 107.54CHF 63.42n/a27
Apr ’25n/a
CHF 76.39
0%
12.60%CHF 106.91CHF 60.97n/a26
Mar ’25n/a
CHF 77.69
0%
12.55%CHF 107.00CHF 61.01n/a27
Feb ’25n/a
CHF 77.73
0%
11.88%CHF 100.23CHF 59.62n/a27
CHF 118.34
Fair Value
0.5% overvalued intrinsic discount
26
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/13 21:41
End of Day Share Price 2026/02/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gilead Sciences, Inc. is covered by 63 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Brian SkorneyBaird
James BirchenoughBarclays